

12. Porsbjerg CM, Sverrild A, Clare M, Lloyd CM, et al. Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics. *Eur Respir J*. 2020 Nov;56(5):1-14. doi: 10.1183/13993003.00260-2020.
13. Chan R, Stewart K, Misirovs R, et al. Targeting Downstream Type 2 Cytokines or Upstream Epithelial Alarmins for Severe Asthma. *J Allergy Clin Immunol Pract*. 10(6), June 2022;1497-1505.
14. Liu S, Verma M, Michalec L, Liu W, Sripathi A, Rollins D, et al. Steroid resistance of airway type 2 innate lymphoid cells from patients with severe asthma: the role of thymic stromal lymphopoietin. *J Allergy Clin Immunol*. 2018;141:257-68.e6.
15. Gauvreau GM, Sehmi R, Ambrose CS, et al. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. *Expert Opin Ther Targets*. 2020;24:777-92.
16. Corren J, Gil GE, Griffiths MJ, et al. Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY. *Ann Allergy Asthma Immunol*. 2021;126,2:187-193.
17. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. *N Engl J Med*. 2021;384:1800-9.
18. Menzies-Gow A, Brightling CE, Ambrose CS, et al. Effect of tezepelumab in oral corticosteroid-dependent patients with severe asthma: results from the phase 3 NAVIGATOR study. *Am J Respir Crit Care Med*. 2021;203:A1442.
19. Wechsler M, Gow AM, Brightling CE, et al. Oral corticosteroid-sparing effect of tezepelumab in adults with severe asthma. *Am J Respir Crit Care Med*. 2021;203:A1197.
20. Tezpire 210 mg injekční roztok v předplněné injekční stříkačce. Souhrn údajů o přípravku. Available from: https://www.ema.europa.eu/en/documents/product-information/tezpire-epar-product-information_cs.pdf [cit. 27. 7. 2023]
21. Diver S, Khalfaoui L, Emson C, et al. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. *Lancet Respir Med*. 2021;9:1299-312.
22. Gauvreau G, Hohlfeld J, Boulet L-P, et al. Late Breaking Abstract—Efficacy of CSJ117 on allergen-induced asthmatic responses in mild atopic asthma patients. *Eur Respir J*. 2020;56 (Suppl 64):3690.
23. Zoumot Z, Busaidi AI N, Tashkandi W, et al. Tezepelumab for patients with severe uncontrolled asthma: a systematic review and meta-analysis. *J Asthma Allergy*. 2022;15:371-379.
24. Préfontaine D, Nadigel J, Chouiali F, et al. Increased IL-33 expression by epithelial cells in bronchial asthma. *J Allergy Clin Immunol*. 2010;125:752-4.
25. Cherry WB, Yoon J, Bartemes KR, et al. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. *J Allergy Clin Immunol*. 2008;121:1484-90.
26. Wechsler ME, Ruddy MK, Pavord ID, et al. Efficacy and safety of itepekimab in patients with moderate-to-severe asthma. *N Engl J Med*. 2021;385:1656-68.
27. Salter BM, Oliveria JP, Nusca G, Smith SG, Tworek D, Mitchell PD, et al. IL-25 and IL-33 induce type 2 inflammation in basophils from subjects with allergic asthma. *Respir Res*. 2016;17:5.
28. Deng C, Peng N, Tang Y, Yu N, et al. Roles of IL-25 in type 2 inflammation and autoimmune pathogenesis. *Front Immunol*. 2021;12:691559.
29. Busse WW, Holgate S, Kerwin E, et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. *Am J Respir Crit Care Med*. 2013;188:1294-302.
30. Khatri SB, Iaccarino JM, Barochia A, et al. Use of fractional exhaled nitric oxide to guide the treatment of asthma: an official American Thoracic Society clinical practice guideline. *Am J Respir Crit Care Med*. 2021;204:e97-109.
31. Shrimanker R, Keene O, Hynes G, et al. Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide, and their combination in severe asthma: a post hoc analysis. *Am J Respir Crit Care Med*. 2019;200:1308-12.
32. Hearn AP, Kavanagh J, d'Ancona G, et al. The relationship between Fenofen and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma. *J Allergy Clin Immunol Pract*. 2021;9:2093-6.
33. FitzGerald JM, Bleecker ER, Menzies-Gow A, et al. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. *Lancet Respir Med*. 2018;6:51-64.

ON-LINE KURZ

On-line kurz Kardiologie

PŘEDNÁŠKY

- **Co je u nových tabulek SCORE opravdu důležité? Modelové situace v ordinaci a jak je řešit** – MUDr. Jaromír Ožana, MUDr. Michal Mačák
- **Speciality v léčbě hypertenze** – doc. MUDr. Ondřej Petrák, Ph.D.
- **Aktuality a praktické tipy v léčbě dyslipidemie** – MUDr. Eva Tůmová, Ph.D.
- **Co (ne)budeme potřebovat od biochemické laboratoře pro stanovení kardiovaskulárního rizika?** – prof. MUDr. Michal Vrablík, Ph.D.

ODBOBNÝ GARANT:

prof. MUDr. Michal Vrablík, Ph.D.
III. interní klinika 1. LF UK a VFN v Praze

POŘADATEL: SOLEN, s. r. o.

POČET
KREDITŮ **2**

Registrace
ZDARMA

TERMÍN
září 2023
až srpen 2024
dostupný na
online.solen.cz

PARTNER

SERVIER
moved by you

